The FDA accepted BioMarin's sNDA to convert Voxzogo from accelerated to full approval for children with achondroplasia, setting a February 28, 2027 decision date — but the San Rafael company faces a newly approved once-weekly competitor and a stock down roughly 9% year-to-date.

San Rafael drugmaker BioMarin Pharmaceutical announced July 13 that the FDA has accepted its supplemental new drug application (sNDA) to convert VOXZOGO® (vosoritide) from accelerated to traditional full approval for children with achondroplasia whose growth plates remain open. The agency set a Prescription Drug User Fee Act target action date of February 28, 2027.

The distinction matters more to payers than to prescribers. The FDA's 2021 accelerated clearance was granted on a surrogate endpoint — annualized growth velocity — a proxy that correlates with clinical benefit but doesn't demonstrate it directly. Full approval requires showing actual clinical benefit: here, adult height. BioMarin says its sNDA package is built on long-term data from three ongoing extension studies — 111-205, 111-208, and 111-302 — and that those trials show mean standing-height gains of approximately 10.6 centimeters after six years and roughly 13.6 centimeters after eight years in children who started Voxzogo after age five, compared with untreated natural-history cohorts, per the company's presentations at medical meetings. No peer-reviewed publication of the full adult-height dataset has been publicly identified as of this writing.

"This submission for VOXZOGO is supported by the largest body of evidence for any medicine in achondroplasia," Greg Friberg, M.D., BioMarin's executive vice president and chief research and development officer, said in the company's announcement. "If approved, VOXZOGO would be the first therapy for achondroplasia to convert from accelerated approval to traditional approval based on a comprehensive clinical data package, including adult height outcomes." Those are company claims; the FDA has not published an independent confirmation of the sNDA acceptance, and the PDUFA notification was disclosed solely through BioMarin's release.

The filing arrives in a tightening market. In February 2026, the FDA approved Ascendis Pharma's YUVIWEL (navepegritide), a once-weekly competitor that directly challenges Voxzogo's daily injection regimen — a real burden in a pediatric population. BioMarin reported $735 million in global Voxzogo revenue in 2024 and posted 26 percent year-over-year growth in full-year 2025, per its fourth-quarter earnings release. Yet BMRN shares were down approximately 9 percent year-to-date as of mid-2026, per ainvest.com, a signal that investors are pricing in competitive erosion. Converting to full approval removes the payer asterisk that comes with an accelerated-approval label and, if the FDA agrees the adult-height data hold up, gives BioMarin a cleaner story at formulary negotiations.

Three things to watch: BioMarin's revenue trajectory through late 2026 will show how much ground YUVIWEL is actually taking before the February 28 decision lands. The peer-reviewed publication of the adult-height outcomes — not just conference slide decks — is the document that will let independent clinicians assess whether those centimeter gains hold under scrutiny. And the FDA's own docket, once updated, will provide the first independent confirmation of what BioMarin announced Sunday.